Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00376454
Recruitment Status : Completed
First Posted : September 14, 2006
Last Update Posted : February 12, 2013
Sponsor:
Information provided by:
GlaxoSmithKline

Brief Summary:
The purpose of this study was to determine the analgesic effect of GW493838 in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery.

Condition or disease Intervention/treatment Phase
Neuropathic Pain Drug: GW493838 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 113 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects With Peripheral Neuropathic Pain
Study Start Date : November 2002
Actual Primary Completion Date : June 2003
Actual Study Completion Date : June 2003



Primary Outcome Measures :
  1. Pain intensity

Secondary Outcome Measures :
  1. Safety Pain relief Global Impression of Change Pain quality Evoked pain intensity Area of allodynia Onset of effect Responder rate Rescue medication pharmacokinetics


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria (subjects must meet all of the following criteria in order to be eligible for this study):

  • Females of non-child-bearing potential
  • diagnosis of peripheral neuropathic pain as a result of: postherpetic neuralgia (PHN) from shingles for at least 3 months duration OR focal neuropathic pain related to nerve injury caused by trauma or surgery
  • defined area of pain

Exclusion criteria

  • discontinue agents for the treatment of neuropathic pain
  • unable to refrain from alcohol and sedative use during the study
  • confounding chronic pain which could not be differentiated from the peripheral neuropathic pain under study
  • intractable pain of unknown origin or active infection in the area of nerve injury.
  • clinically significant medical history or abnormality found on physical examination, laboratory assessment or ECG at Screening or Baseline
  • severe asthma that has required oral corticosteroid use in the last 12 months or the subject had severe asthma that required, at anytime, hospitalization or mechanical ventilation support.
  • clinical evidence of major depression (by medical history) except those subjects controlled by SSRIs.
  • a known allergy or hypersensitivity to any of the investigational products (including rescue analgesia- acetaminophen), or pharmacological class of the investigational product (i.e. adenosine) and/or investigational product excipients.
  • a clinically significant abuse of substances, defined as: Patterns of substance intake consistent with disruption of normal function in society; Past or current impairment of organ function reasonably related to substance intake; Any indication of difficulty in abstaining from substances for the duration of the study.
  • had previously participated in a clinical study during the past 30 days in which the subject was exposed to an investigational or non-investigational drug or device
  • currently participating in another clinical study in which the subject was exposed to an investigational or non-investigational drug or device
  • prior blood reduction (450 mL or more) during the previous 30 days
  • at risk of non-compliance
  • a woman of childbearing potential or a woman who was lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376454


Locations
Layout table for location information
United States, Alabama
GSK Clinical Trials Call Center
Huntsville, Alabama, United States, 35801
United States, Arizona
GSK Clinical Trials Call Center
Hot Springs, Arizona, United States, 71913
United States, Arkansas
GSK Clinical Trials Call Center
Little Rock, Arkansas, United States, 72205
United States, California
GSK Clinical Trials Call Center
La Jolla, California, United States, 92037
GSK Clinical Trials Call Center
Oceanside, California, United States, 92056
United States, Colorado
GSK Clinical Trials Call Center
Boulder, Colorado, United States, 80304
United States, Florida
GSK Clinical Trials Call Center
Fort Lauderdale, Florida, United States, 33308
GSK Clinical Trials Call Center
Ft. Myers, Florida, United States, 33916
GSK Clinical Trials Call Center
Palm Beach Gardens, Florida, United States, 33410
GSK Clinical Trials Call Center
Palm Beach, Florida, United States, 33409
GSK Clinical Trials Call Center
Pembroke Pines, Florida, United States, 33024
GSK Clinical Trials Call Center
S. Daytona, Florida, United States, 32119
GSK Clinical Trials Call Center
St. Petersburg, Florida, United States, 33701
GSK Clinical Trials Call Center
West Palm Beach, Florida, United States, 33407
United States, Indiana
GSK Clinical Trials Call Center
Evansville, Indiana, United States, 47712
United States, Kentucky
GSK Clinical Trials Call Center
Lexington, Kentucky, United States, 40503
GSK Clinical Trials Call Center
Louisville, Kentucky, United States, 40202
GSK Clinical Trials Call Center
Louisville, Kentucky, United States, 40205
United States, Louisiana
GSK Clinical Trials Call Center
Covington, Louisiana, United States, 70433
United States, Massachusetts
GSK Clinical Trials Call Center
Boston, Massachusetts, United States, 02115
United States, Nevada
GSK Clinical Trials Call Center
Henderson, Nevada, United States, 89052
United States, New Hampshire
GSK Clinical Trials Call Center
Lebanon, New Hampshire, United States, 03766
United States, New Jersey
GSK Clinical Trials Call Center
Ridgewood, New Jersey, United States, 07450
United States, New York
GSK Clinical Trials Call Center
Albany, New York, United States, 12205
United States, North Carolina
GSK Clinical Trials Call Center
Asheville, North Carolina, United States, 28803
GSK Clinical Trials Call Center
Winston-Salem, North Carolina, United States, 27103
United States, Oklahoma
GSK Clinical Trials Call Center
Tulsa, Oklahoma, United States, 74104
United States, Pennsylvania
GSK Clinical Trials Call Center
Altoona, Pennsylvania, United States, 16601
GSK Clinical Trials Call Center
Duncansville, Pennsylvania, United States, 16635
United States, Texas
GSK Clinical Trials Call Center
Richardson, Texas, United States, 75080
United States, Washington
GSK Clinical Trials Call Center
Tacoma, Washington, United States, 98405
United States, Wisconsin
GSK Clinical Trials Call Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00376454    
Other Study ID Numbers: A1A20004
First Posted: September 14, 2006    Key Record Dates
Last Update Posted: February 12, 2013
Last Verified: February 2013
Keywords provided by GlaxoSmithKline:
neuropathic pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuralgia
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Pain
Neurologic Manifestations